Texas Permanent School Fund Corp Acquires 6,688 Shares of Repligen Corporation $RGEN

Texas Permanent School Fund Corp lifted its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 36.2% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 25,141 shares of the biotechnology company’s stock after acquiring an additional 6,688 shares during the quarter. Texas Permanent School Fund Corp’s holdings in Repligen were worth $3,127,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Squarepoint Ops LLC boosted its position in Repligen by 49.7% during the second quarter. Squarepoint Ops LLC now owns 73,792 shares of the biotechnology company’s stock worth $9,178,000 after purchasing an additional 24,510 shares during the period. Headlands Technologies LLC acquired a new stake in shares of Repligen during the 2nd quarter worth about $353,000. Tower Research Capital LLC TRC boosted its holdings in shares of Repligen by 14.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,448 shares of the biotechnology company’s stock worth $180,000 after buying an additional 179 shares during the period. Captrust Financial Advisors grew its stake in Repligen by 16.8% in the 2nd quarter. Captrust Financial Advisors now owns 6,566 shares of the biotechnology company’s stock valued at $817,000 after buying an additional 946 shares during the last quarter. Finally, Tidal Investments LLC grew its stake in Repligen by 13.7% in the 2nd quarter. Tidal Investments LLC now owns 5,160 shares of the biotechnology company’s stock valued at $642,000 after buying an additional 621 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Stock Performance

NASDAQ:RGEN opened at $162.38 on Friday. The company has a market cap of $9.14 billion, a price-to-earnings ratio of 8,123.06, a PEG ratio of 3.55 and a beta of 1.11. Repligen Corporation has a fifty-two week low of $102.96 and a fifty-two week high of $182.52. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.14 and a current ratio of 8.36. The stock has a fifty day moving average price of $157.09 and a 200-day moving average price of $135.84.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.42 by $0.04. The company had revenue of $188.81 million for the quarter, compared to analysts’ expectations of $181.23 million. Repligen had a return on equity of 4.66% and a net margin of 0.25%.Repligen’s revenue was up 21.9% on a year-over-year basis. During the same quarter last year, the business earned $0.43 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. As a group, equities analysts anticipate that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Insider Buying and Selling at Repligen

In other news, COO James Bylund sold 2,191 shares of the business’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $151.21, for a total value of $331,301.11. Following the completion of the transaction, the chief operating officer directly owned 21,520 shares in the company, valued at approximately $3,254,039.20. The trade was a 9.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Anthony Hunt sold 25,000 shares of the stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $156.88, for a total transaction of $3,922,000.00. Following the sale, the director owned 100,743 shares in the company, valued at $15,804,561.84. This represents a 19.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 49,657 shares of company stock valued at $7,721,077 in the last ninety days. 1.20% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Evercore ISI boosted their price objective on Repligen from $155.00 to $175.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. Canaccord Genuity Group boosted their price target on Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a research note on Wednesday, October 29th. Barclays upped their price objective on Repligen from $175.00 to $200.00 and gave the company an “overweight” rating in a report on Monday. Hsbc Global Res raised Repligen to a “strong-buy” rating in a report on Wednesday, October 1st. Finally, HC Wainwright restated a “buy” rating and issued a $180.00 price target on shares of Repligen in a research note on Wednesday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $177.92.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.